DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jvp63j/antibodies_in) has announced the addition of the "Antibodies in Oncology: Drug Pathway Analyzer 2014" report to their offering.
Extra value: One year of free online updates included with this product
There are today at least 608 antibody drugs known to affect more than 206 specific intracellular signaling pathways for the treatment of more than 107 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 264 drug targets that are included in this drug-pathway analyzing tool. No less than 259 of these have been recorded with mutations and 32 drug targets have mutations which have been causally implicated in cancer.
Pathway Coverage
- BioCarta # 192 Pathways
- KEGG # 156 Pathways
- NCI-Nature # 206 Pathways
- NetPath # 31 Pathways
Pipeline Coverage
- Marketed # 21
- Pre-registration # 3
- Phase III # 41
- Phase II # 116
- Phase I # 174
- Preclinical # 213
- No Data # 3
- Suspended # 6
-
Ceased # 165
You Use this Analyzer Tool of Antibody Drugs to:
- Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties
- Uncover potential indication expansion areas for your drug portfolio
- Reveal repositioning opportunities for your older, shelved drugs
- Evaluate the progression and success of targeting certain pathways by different tumor types
- Investigate drugs which affect crosstalk between key pathways
- Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.
- Find possible adjuvant therapy settings with other drugs.
For more information visit http://www.researchandmarkets.com/research/jvp63j/antibodies_in
